Dose adjustment based on a patient's renal function is a very current example of personalising therapy. While this kind of precision medicine holds great potential, it is often overlooked, particularly in younger patients. Darcie Streetman and Rachel Eyler explore the growing knowledge and tools available for optimising renal dosing.
A new, pooled analysis of data from Novo Nordisk’s Phase III trials SUSTAIN 6 and PIONEER 6 shows that semaglutide may help patients with type 2 diabetes live longer without a cardiovascular event. PharmaTimes talks to lead study investigator Dr Jan Westerink about the importance of these findings